Premature Ejaculation Clinical Trial
Official title:
Effect of Tamsulosin on Premature Ejaculation Compared With Paroxetine Hydrochloride
A study to compare the effect of tamsulosin versus the effect of paroxetine hydrochloride and the effect of combination of them on PE.
Premature ejaculation is considered the most common male sexual disorder. affecting
approximately 4-39 % of men in general community. In 2008, the International Society for
Sexual Medicine defined premature ejaculation as a male sexual dysfunction that is
characterized by ejaculation that always or nearly always occurs within or before 1 minute of
vaginal penetration. Moreover it is associated with presence of distress, frustration,
bother, negative personal consequences, depression and the avoidance of sexual intimacy.
Many etiological theories have been included in the pathogenesis of premature ejaculation:
neurobiological, psychological, environmental and endocrine factors. So a lot of therapeutic
modalities, such as behavioral therapy, selective serotonin reuptake inhibitors (SSRIs),
adrenergic alpha 1 antagonists, local anesthetic creams, clomipramine, phosphodiesterase type
5 inhibitors and centrally acting analgesics have been used for the treatment of premature
ejaculation.
Previous studies reported that tamsulosin which is alpha blocker agent used as primary
therapeutic agent for BPH is effective in the improvement of sexual function. However studies
on the effect of tamsulosin on ejaculation reported that tamsulosin had inhibitory effect in
the emission phase of ejaculation including decreased ejaculatory volume. So inhibitory
effect of tamsulosin on ejaculation may be beneficial to patients suffering from premature
ejaculation.
Historically, PE was considered psychological problem and was treated by behavioral treatment
and psychotherapy but there is pharmacological studies increase the evidence that PE may be
related to decreased serotonergic neurotransmission. So selective serotonin reuptake
inhibitors (SSRIs ) such as : paroxetine, fluoxetine, dapoxetine, and sertraline are among
the recommended pharmacological treatments for treating PE. But there is no universal
agreement on the type, the dose and administration protocol.
So a study is needed to compare the value of combination therapy of both tamsulosin and
paroxetine with the value of single therapy of either of them and consider Intravaginal
Ejaculatory Latency Time (IELT) and ejaculatory control ability of patients after using
tamsulosin and paroxetine.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232425 -
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
|
Phase 2 | |
| Completed |
NCT01439984 -
Trial of PED-1 in Male Patients With Premature Ejaculation
|
Phase 3 | |
| Completed |
NCT01184105 -
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
|
Phase 1 | |
| Completed |
NCT01203202 -
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
|
Phase 2 | |
| Completed |
NCT03942367 -
Evaluation of the Safety and Effectiveness of the vPatch Device
|
N/A | |
| Completed |
NCT02939495 -
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy
|
Phase 4 | |
| Completed |
NCT02572037 -
Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
|
||
| Recruiting |
NCT02581826 -
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
|
Phase 2 | |
| Terminated |
NCT00983736 -
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
|
Phase 3 | |
| Completed |
NCT00556478 -
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
|
Phase 2/Phase 3 | |
| Completed |
NCT00549211 -
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
|
Phase 1 | |
| Not yet recruiting |
NCT05556083 -
Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)
|
Phase 2 | |
| Completed |
NCT03304808 -
Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0
|
N/A | |
| Completed |
NCT00861484 -
Proof of Mechanism in ELT
|
Phase 1 | |
| Completed |
NCT02984592 -
Effect of Exercise on Premature Ejaculation
|
N/A | |
| Recruiting |
NCT02571101 -
A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation
|
Phase 2 | |
| Completed |
NCT03174470 -
Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
|
N/A | |
| Completed |
NCT02794454 -
A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
|
N/A | |
| Completed |
NCT02297152 -
A New Treatment for Premature Ejaculation?
|
N/A | |
| Not yet recruiting |
NCT00656552 -
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation
|
Phase 0 |